All Releases
 |
Rockwell Medical Reports First Quarter 2012 Results
May 3, 2012
|
25.1 KB |
|
| |
WIXOM, Mich., May 3, 2012 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis, announced today its results f...
|
|
Rockwell Medical Schedules Earnings Conference Call
May 1, 2012
|
19.7 KB |
|
| |
WIXOM, MI, May 1, 2012 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis, announced today that it will hol...
|
|
Rockwell Medical Completes Patient Enrollment in PRIME Clinical Study
Apr 30, 2012
|
11.4 KB |
|
| |
WIXOM, MI -- (Marketwire) -- 04/30/12 --
Rockwell Medical (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis, announced today that it has ...
|
|
Rockwell Medical Appoints Raymond Pratt, M.D. FACP as Chief Medical Officer
Apr 19, 2012
|
19.2 KB |
|
| |
WIXOM, Mich., April 19, 2012 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency and secondary hyperparathyroidism, announced today that it has hired Raymon...
|
|
Rockwell Medical Data Safety Monitoring Board Recommends SFP Phase III Efficacy Studies to Continue as Planned
Mar 19, 2012
|
15.7 KB |
|
| |
WIXOM, Mich., March 19, 2012 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency and secondary hyperparathyroidism, today announced that the independent Dat...
|
|
Rockwell Medical Reports 2011 and Fourth Quarter Results
Mar 1, 2012
|
27.3 KB |
|
| |
WIXOM, Mich., March 1, 2012 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency and secondary hyperparathyroidism, announced today its results for the fourt...
|
|
Rockwell Medical Closes $17.5 million Registered Common Stock Offering
Feb 15, 2012
|
15.9 KB |
|
| |
WIXOM, Mich., Feb. 15, 2012 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency and secondary hyperparathyroidism, announced today that it has completed its...
|
|
Rockwell Medical Prices Registered Common Stock Offering
Feb 9, 2012
|
15.8 KB |
|
| |
WIXOM, Mich., Feb. 9, 2012 (GLOBE NEWSWIRE) -- Rockwell Medical Technologies, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency and secondary hyperparathyroidism, announced today that it...
|
|
Rockwell Medical Schedules Conference Call Reporting Fourth Quarter and Year End Results
Jan 27, 2012
|
15.7 KB |
|
| |
WIXOM, Mich., Jan. 27, 2012 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency and secondary hyperparathyroidism, announced today that it will hold an inve...
|
|
Rockwell Medical Data Safety Monitoring Board Recommends Phase III CRUISE Studies Continue as Planned
Dec 12, 2011
|
15.4 KB |
|
| |
WIXOM, Mich., Dec. 12, 2011 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency and secondary hyperparathyroidism, today announced that the independent Data...
|
|
Rockwell Medical Reports Third Quarter 2011 Results
Nov 3, 2011
|
28.9 KB |
|
| |
WIXOM, Mich., Nov. 3, 2011 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency and secondary hyperparathyroidism, today announced results for the third quar...
|
|
Rockwell Medical Schedules Conference Call
Oct 28, 2011
|
19.0 KB |
|
| |
WIXOM, Mich., Oct. 28, 2011 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD) and iron deficiency anemia, announced today that it will hold an investor conference call on Thursday, November ...
|
|
Rockwell Medical to Present at JMP Securities Healthcare Conference
Sep 21, 2011
|
15.1 KB |
|
| |
WIXOM, Mich., Sept. 21, 2011 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron-deficiency anemia, announced today that Robert L. Chioini, Chairman and Chief Executive Officer, alon...
|
|
Rockwell Medical Appoints Annamaria T. Kausz, M.D., M.S. to VP of Drug Development and Medical Affairs
Sep 19, 2011
|
17.3 KB |
|
| |
WIXOM, Mich., Sept. 19, 2011 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ERSD), chronic kidney disease (CKD), and iron deficiency anemia, announced today that it has hired Annamaria T. Kausz, M.D., M.S. as Vice President...
|
|
Rockwell Medical to Present at Wedbush Life Sciences Management Access Conference
Aug 11, 2011
|
16.5 KB |
|
| |
WIXOM, Mich., Aug. 11, 2011 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron-deficiency anemia, today announced that Rob Chioini, Chairman and Chief Executive Officer, along with ...
|
|
Rockwell Medical Reports Second Quarter 2011 Results
Aug 4, 2011
|
30.9 KB |
|
| |
WIXOM, Mich., Aug. 4, 2011 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD) and iron deficiency anemia, today announced results for the second quarter ended June 30, 2011.
Second Qu...
|
|
Rockwell Medical Schedules Investor Conference Call
Jul 28, 2011
|
19.6 KB |
|
| |
WIXOM, Mich., July 28, 2011 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD) and iron deficiency anemia, announced today that it will hold an investor conference call on Thursday, August 4t...
|
|
Rockwell Medical Announces Acquisition of Generic Drug Vitamin-D to Treat Secondary Hyperparathyroidism in ESRD Patients
Jul 26, 2011
|
17.6 KB |
|
| |
WIXOM, Mich., July 26, 2011 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia, announced today that it has acquired an Abbreviated New Drug Application (ANDA) for...
|
|
Rockwell Medical Gains Membership Into the Russell 2000 Index
Jun 29, 2011
|
16.1 KB |
|
| |
WIXOM, Mich., June 29, 2011 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron-deficiency anemia, today announced that the Company was added to the Russell 2000® Index at the c...
|
|
Rockwell Medical Announces U.S. Patent Issued for SFP Packaging and Method of Use
May 11, 2011
|
18.7 KB |
|
| |
WIXOM, Mich., May 11, 2011 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia, announced today that it has received notice from the U.S. Patent and Trademark Offic...
|
|
|
=add release to Briefcase |
| Stock Information |
| NASDAQ : RMTI |
|
$7.53
- 0.25
|
| Delayed at least 20min., by eSignal. |
|
SFP Mode of Action
|
